tbuckley/cabot-search huggingface dataset:
The firm: extended surgical teams improve training and patient care
Authors: Bill Allum, Ian Eardley, Derek Alderson, Neil Mortensen
Journal: BMJ (2019)

Rimmer asks whether bringing back the firm could improve teamwork and morale.1 Considerable evidence shows that working in a multidisciplinary team improves patient experience, safety, productivity, and the working lives of all involved.

In 2016 the Royal College of Surgeons of England assessed the contribution of the extended surgical team,2 which includes both medically and non-medically …
Substantial Differences Between Cohorts of Patients Hospitalized With Heart Failure in Canada and the United States
Authors: Zhenqiu Lin, Shu-Xia Li
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
The prognostic impact of hypoxia-inducible factor-1α and VEGF, IGF-2, p21, p53 expression in gastric adenocarcinoma
Authors: Y. Kakeji, K. Mizokami, Y. Sumiyoshi, K. Yoshinaga, H. Saeki, E. Tokunaga, K. Endo, M. Morita, H. Kitao, Y. Emi, Y. Maehara
Journal: Journal of Clinical Oncology (2009)

4571 Background: Hypoxia caused by either radiation or chemotherapy induces various intracellular adaptive responses, which contribute to tumor progression. The clinicopathological characteristics of human gastric cancer and the clinical outcomes were analyzed to investigate the effects of the expression of hypoxia-inducible factor1α (HIF-1α) and some related proteins, such as, vascular endothelial growth factor (VEGF), insulin-like growth factor-2 (IGF-2), p21, and p53 on the prognosis of human gastric cancer. Methods: The expressions of HIF-1α, VEGF, IGF-2, p21, and p53 proteins were determined by immunohistochemistry in 216 specimens of primary gastric cancer. Results: Of all 216 patients, 85 (39.4%) showed a positive expression of HIF-1α. In addition, the HIF-1α expression positively correlated with the tumor size and depth of invasion, while it was also more frequent in tumors with lymphatic invasion and undifferentiated adenocarcinomas. Though the VEGF expression significantly correlated with the HIF-1α expression, the expressions of IGF-2, p21 and p53 did not show any correlation. HIF-1α-positive/p21-negative tumors had a lower apoptotic index, and the patients with such tumors also had a significantly poorer prognosis. Similarly, HIF-1α-positive/p53-positive tumors had a significantly poorer prognosis. A multivariate Cox regression analysis showed the depth of invasion, lymph node metastasis, and HIF-1α positivity to all be independent prognostic factors in patients with gastric cancer. Conclusions: Based on the above findings, HIF-1α is therefore considered to be a useful independent prognostic factor in gastric cancer, and the combination of a HIF-1α protein overexpression with the loss of p21 expression or nonfunctional p53 thus tends to indicate a dismal prognosis. Controlling hypoxia, especially in the HIF-1α pathways, may therefore hold the key to a greater individualization of therapy and also lead to the development of new treatments for patients with gastric cancer. No significant financial relationships to disclose.
An extensive perioral rash
Authors: Nicholas Beng-Hui Ng, Wee-Song Yeo
Journal: BMJ (2019)

A 15 year old girl presented with a painful rash around her mouth. It started as a small blister at the corner of her right lip and progressed within 48 hours to the appearance seen in fig 1. She also had several painful ulcers on the buccal mucosa. At presentation she had low grade pyrexia of 38°C. The ulcers prevented her from eating solids but she was able to tolerate fluids.



Fig 1 
Perioral rash



Further history revealed that she was diagnosed with nephrotic syndrome six years earlier, and had experienced multiple relapses. In accordance with local nephrotic syndrome protocols, she had required …
Evaluation and Prognostic Relevance of Right Ventricular–Arterial Coupling in Pulmonary Hypertension
Authors: Manuel J. Richter, Dana Peters, Hossein A. Ghofrani, Robert Naeije, Fritz Roller, Natascha Sommer, Henning Gall, Friedrich Grimminger, Werner Seeger, Khodr Tello
Journal: American Journal of Respiratory and Critical Care Medicine (2019)
Hemolysis-associated hemoglobin cast nephropathy results from a range of clinicopathologic disorders
Authors: Zeljko Dvanajscak, Patrick D. Walker, L. Nicholas Cossey, Nidia C. Messias, Christie L. Boils, Michael B. Kuperman, Christopher P. Larsen
Journal: Kidney International (2019)

Intravascular hemolysis is relatively rare but can lead to acute kidney injury (AKI), from increased destruction of erythrocytes and release of free hemoglobin. Since hemolysis and hemoglobinuria are known causes of acute kidney injury we sought to define clinicopathologic findings and outcomes of patients with hemolysis-associated hemoglobin cast nephropathy through a retrospective analysis of 27 cases. The mean patient age was 47 years (range 19-79) and the female-to-male ratio was 1.3:1. All patients presented with AKI with a mean serum creatinine of 8.0 (range 2.9-17.0) mg/dL. Etiologies included autoimmune hemolytic anemia (30%), medication (26%), paroxysmal nocturnal hemoglobinuria (7%), procedural/mechanical causes (7%), transfusion of incompatible blood (4%), toxin ingestion (4%), disseminated intravascular coagulation (4%), and hemoglobinopathy (4%). All biopsies showed acute tubular injury and pigmented, proteinaceous casts characterized by positive hemoglobin immunohistochemistry. After a mean follow-up of nine months (range 0.5-26), the mean serum creatinine was 1.3 (range 0.6-3.3) mg/dL, with 78% of patients returning to normal kidney function. Thus, based on our clinicopathologic case series, hemolysis-associated hemoglobin cast nephropathy is an important entity for clinicians and pathologists to recognize as treatment hinges upon elimination of the pathogenic driver of intravascular hemolysis.
Abstract 21416: Variation Across Centers and Predictors of Initial Immunosuppression Strategy After Heart Transplant
Authors: Brian Wayda, Autumn Clemons, Raymond C Givens, Koji Takeda, Hiroo Takayama, Farhana Latif, Susan Restaino, Yoshifumi Naka, A. Reshad Garan, Melana Yuzefpolskaya, Maryjane A Farr, Paolo C Colombo, Veli K Topkara
Journal: Circulation (2017)

Background: There are multiple accepted immunosuppressive medication (ISM) strategies after heart transplant (HT) and evidence of their relative efficacy is limited. As a result, ISM strategies may vary considerably depending on local protocols. We aimed to characterize center-level variation and predictors of ISM strategy. Methods: Using data from the UNOS registry, we included 38,826 patients undergoing HT at 124 US centers from 1994 to 2014; centers with less than 30 transplants during this span were excluded (n=53). ISM strategies included 1) use of anti-lymphocyte induction therapy, 2) omission of corticosteroids (“steroid-free”) in the initial maintenance regimen, and 3) initial inclusion of mTOR inhibitors. Associations between the utilization of each strategy and other center-level characteristics were determined using chi-squared and Pearson correlation tests. Results: The mean center-level proportions of patients receiving induction, steroid-free, and mTOR inhibitor regimens were 50.2% (standard deviation (SD) = 24.6%), 4.3% (SD = 5.6%), and 2.4% (SD = 3.2%) respectively (Figure 1). Many centers (16.1%) used induction in nearly all (&gt; 80%) of their patients and a similar proportion (21.0%) used induction infrequently (in &lt; 20% of patients). While use of mTOR and steroid-free regimens was rare, 10 centers used one or both of these regimens in more than 10% of patients. Centers in the northeast less often used induction and steroid-free regimens were more often used in higher-volume centers (p &lt;= 0.05). Conclusions: There is substantial variation across centers in ISM strategy after HT, particularly in the use of induction. This degree of variation is unlikely to be explained by differences in patient mix, and more likely stems from differences in provider preference. Further studies are needed to assess the underlying drivers and clinical impact of this variation.
MCC-134, a Single Pharmacophore, Opens Surface ATP–Sensitive Potassium Channels, Blocks Mitochondrial ATP–Sensitive Potassium Channels, and Suppresses Preconditioning
Authors: NorihitoSasaki, MitsushigeMurata, YiruGuo, Su-HyunJo, AndreasOhler, MasaharuAkao, BrianO’Rourke, Rui-PingXiao, RobertoBolli, EduardoMarbán
Journal: Circulation (2003)

Background— MCC-134 (1-[4-(H-imidazol-1-yl)benzoyl]-N-methylcyclobutane-carbothioamide), a newly developed analog of aprikalim, opens surface smooth muscle–type ATP-sensitive potassium (KATP) channels but inhibits pancreatic KATP channels. However, the effects of MCC-134 on cardiac surface KATP channels and mitochondrial KATP (mitoKATP) channels are unknown. A mixed agonist/blocker with differential effects on the two channel types would help to clarify the role of KATP channels in cardioprotection. Methods and Results— To index mitoKATP channels, we measured mitochondrial flavoprotein fluorescence in rabbit ventricular myocytes. MCC-134 alone had little effect on basal flavoprotein fluorescence. However, MCC-134 inhibited diazoxide-induced flavoprotein oxidation in a dose-dependent manner (EC50=27 μmol/L). When ATP was included in the pipette solution, MCC-134 slowly activated surface KATP currents with some delay (>10 minutes). These results indicate that MCC-134 is a mitoKATP channel inhibitor and a su...
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Authors: Jing He, Ruijun Zhang, Miao Shao, Xiaozhen Zhao, Miao Miao, Jiali Chen, Jiajia Liu, Xiaoying Zhang, Xia Zhang, Yuebo Jin, Yu Wang, Shilei Zhang, Lei Zhu, Alexander Jacob, Rulin Jia, Xujie You, Xue Li, Chun Li, Yunshan Zhou, Yue Yang, Hua Ye, Yanying Liu, Yin Su, Nan Shen, Jessy Alexander, Jianping Guo, Julian Ambrus, Xin Lin, Di Yu, Xiaolin Sun, Zhanguo Li
Journal: Annals of the Rheumatic Diseases (2019)

Objectives Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. Methods A randomised, double-blind and placebo-controlled clinical trial was designed to treat 60 patients with active SLE. These patients received either IL-2 (n=30) or placebo (n=30) with standard treatment for 12 weeks, and were followed up for additional 12 weeks. IL-2 at a dose of 1 million IU or placebo was administered subcutaneously every other day for 2 weeks and followed by a 2-week break as one treatment cycle. The primary endpoint was the SLE Responder Index-4 (SRI-4) at week 12. The secondary endpoints were other clinical responses, safety and dynamics of immune cell subsets. Results At week 12, the SRI-4 response rates were 55.17% and 30.00% for IL-2 and placebo, respectively (p=0.052). At week 24, the SRI-4 response rate of IL-2 group was 65.52%, compared with 36.67% of the placebo group (p=0.027). The primary endpoint was not met at week 12. Low-dose IL-2 treatment resulted in 53.85% (7/13) complete remission in patients with lupus nephritis, compared with 16.67% (2/12) in the placebo group (p=0.036). No serious infection was observed in the IL-2 group, but two in placebo group. Besides expansion of regulatory T cells, low-dose IL-2 may also sustain cellular immunity with enhanced natural killer cells. Conclusions Low-dose IL-2 might be effective and tolerated in treatment of SLE. Trial registration number ClinicalTrials.gov Registries ( NCT02465580 and NCT02932137 ).
Prognostic Impact of TP53 Mutation in Combination with Chromosome 17p Deletion in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Authors: Seongseok Yun, Jose Sandoval-Sus, Todd C Knepper, Jamie Teer, Julio C. Chavez, Javier Pinilla-Ibarz
Journal: Blood (2017)
Balancing confidence and conservatism: idiopathic scoliosis in an adult powerlifter
Authors: Rohit Malyala
Journal: British Journal of Sports Medicine (2019)

Growing up I had never given much thought to occasional back pains, nor to the asymmetries of my body, whether I noticed it in my legs, my ribs or my shoulders. Pain was as irritating to me as it might be for anybody else, but without an explanation for the experience, it was easy to not let the sensations overwhelm me. Everybody experiences discomfort every now and again, and mine were certainly not debilitating enough to change anything about my life.

One day, while being treated for an unrelated wrist injury, my family doctor noticed some of those asymmetries. While the growing pain had generally stopped—I was 17 now—she referred me for an X-ray, and I obliged. In the follow-up I was told that I had scoliosis, with two curves. I was told that there was a risk of the curves progressing, and that I should take steps to avoid such progression. She referred me to a community physiotherapist, and recommended that I self-monitor my posture. I obliged again, attending physiotherapy three times a week. I also started to avoid engaging in other physical activities.

My curves, with hindsight, were not at all severe. But at the time, I grew fearful. My mind …
Case 29-2019: A 14-Month-Old Boy with Vomiting
Authors: Carlo Di Lorenzo, Batul Kaj, Kumar Krishnan, Christopher J. Moran, Allan M. Goldstein, Michael S. Gee, Ricard Masia
Journal: New England Journal of Medicine (2019)

A 14-month-old boy was evaluated in the pediatric gastroenterology clinic because of vomiting. Beginning at 26 days of age, frequent episodes of emesis occurred, and the boy's parents once reported blood in the vomitus. He had difficulty gaining weight but was otherwise healthy. Diagnostic studies were performed.
Inhibition of the Enzyme Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia
Authors: David B. Sykes, Youmna Sami Kfoury, Francois Mercier, Mathias Wawer, Amir Schajnovitz, Hanna Meyer, Kerry A Pierce, Detlef Stoeckigt, Clary B Clish, Paul A Clemons, Andreas Janzer, David T. Scadden
Journal: Blood (2016)
Thiotepa, Busulfan, and Cyclophosphamide and Busulfan, Cyclophosphamide, Etoposide As Autologous Stem Cell Transplantation Conditioning Regimen in Primary Central Nervous System Lymphoma
Authors: Jaewon Hyung, Jung Yong Hong, Dok Hyun Yoon, Kyoungmin Lee, Shin Kim, Chan-Sik Park, Jooryung Huh, Jin-Sook Ryu, Cheolwon Suh
Journal: Blood (2017)
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Authors: Christopher A. Eide, Matthew S. Zabriskie, Samantha L. Savage Stevens, Orlando Antelope, Nadeem A. Vellore, Hein Than, Anna Reister Schultz, Phillip Clair, Amber D. Bowler, Anthony D. Pomicter, Dongqing Yan, Anna V. Senina, Wang Qiang, Todd W. Kelley, Philippe Szankasi, Michael C. Heinrich, Jeffrey W. Tyner, Delphine Rea, Jean-Michel Cayuela, Dong-Wook Kim, Cristina E. Tognon, Thomas O'Hare, Brian J. Druker, Michael W. Deininger
Journal: Cancer Cell (2019)
Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’
Authors: Mariano J. Alvarez, Pengrong Yan, Mary L. Alpaugh, Michaela Bowden, Ewa Sicinska, Chensheng W. Zhou, Charles Karan, Ronald B. Realubit, Prabhjot S. Mundi, Adina Grunn, Dirk Jäger, John A. Chabot, Antonio T. Fojo, Paul E. Oberstein, Hanina Hibshoosh, Jeffrey W. Milsom, Matthew H. Kulke, Massimo Loda, Gabriela Chiosis, Diane L. Reidy-Lagunes, Andrea Califano
Journal: Nature Genetics (2019)
Peritoneal GATA6+ macrophages function as a portal for Staphylococcus aureus dissemination
Authors: Selina K. Jorch, Bas G.J. Surewaard, Mokarram Hossain, Moritz Peiseler, Carsten Deppermann, Jennifer Deng, Ania Bogoslowski, Fardau van der Wal, Abdelwahab Omri, Michael J. Hickey, Paul Kubes
Journal: Journal of Clinical Investigation (2019)

Essentially all Staphylococcus aureus (S. aureus) bacteria that gain access to the circulation are plucked out of the bloodstream by the intravascular macrophages of the liver - the Kupffer cells. It is also thought that these bacteria are disseminated via the bloodstream to other organs. Our data show that S. aureus inside Kupffer cells grew and escaped across the mesothelium into the peritoneal cavity and immediately infected GATA-binding factor 6-positive (GATA6+) peritoneal cavity macrophages. These macrophages provided a haven for S. aureus, thereby delaying the neutrophilic response in the peritoneum by 48 hours and allowing dissemination to various peritoneal and retroperitoneal organs including the kidneys. In mice deficient in GATA6+ peritoneal macrophages, neutrophils infiltrated more robustly and reduced S. aureus dissemination. Antibiotics administered i.v. did not prevent dissemination into the peritoneum or to the kidneys, whereas peritoneal administration of vancomycin (particularly liposomal vancomycin with optimized intracellular penetrance capacity) reduced kidney infection and mortality, even when administered 24 hours after infection. These data indicate that GATA6+ macrophages within the peritoneal cavity are a conduit of dissemination for i.v. S. aureus, and changing the route of antibiotic delivery could provide a more effective treatment for patients with peritonitis-associated bacterial sepsis.
Abstract 12801: QT, JTpeak, And TpTe Prolongation mediated by hERG Potassium Channel Blockers
Authors: Yinn Shaung Ooi, Amanulla Khaji, Gan-Xin Yan
Journal: Circulation (2018)

Introduction: QT prolongation corrected for heart rate (QTc) is a sensitive marker for drug-induced torsade de pointes (TdP). However, it is not specific as QTc prolonging drugs that block inward currents in addition to hERG potassium channels are often not associated with TdP. Prolongation of JTpea
Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China
Authors: M.F. Ji, W. Sheng, W.M. Cheng, M.H. Ng, B.H. Wu, X. Yu, K.R. Wei, F.G. Li, S.F. Lian, P.P. Wang, W. Quan, L. Deng, X.H. Li, X.D. Liu, Y.L. Xie, S.J. Huang, S.X. Ge, S.L. Huang, X.J. Liang, S.M. He, H.W. Huang, S.L. Xia, P.S. Ng, H.L. Chen, S.H. Xie, Q. Liu, M.H. Hong, J. Ma, Y. Yuan, N.S. Xia, J. Zhang, S.M. Cao
Journal: Annals of Oncology (2019)

BackgroundPrevious mass screening studies have shown that IgA antibodies against Epstein–Barr Virus (EBV) can facilitate early detection of nasopharyngeal carcinoma (NPC), but the impact of EBV-antibody screening for NPC-specific mortality remains unknown.Patients and methodsA prospective, cluster randomized, controlled trial for NPC screening (PRO-NPC-001) was conducted in 3 selected towns of Zhongshan City and 13 selected towns of Sihui City in southern China beginning in 2008. Serum samples of the screening group were tested for two previously selected anti-EBV antibodies. Subjects with serological medium risk were subsequently retested annually for 3 years, and those with serological high risk were referred to otorhinolaryngologists for diagnostic check-up. An interim analysis was carried out to evaluate the primary end points of the NPC-specific mortality and the early diagnostic rate, and the secondary end point of the NPC incidence, through linkage with the database of Zhongshan City.ResultsAmong 70 296 total subjects, 29 413 screened participants (41.8% of the total subjects) in the screening group and 50 636 in the control group, 153 (43.3 per 100 000 person-year), 62 (55.3 per 100 000 person-year) and 99 (33.1 per 100 000 person-year) NPC cases were identified. The early diagnostic rates of NPC were significantly higher in the participants (79.0%, P < 0.0001) and the screening group (45.9%, P < 0.0001) compared with the control group (20.6%). Although no differences were found between NPC-specific mortality of the screening group and the control group [relative risk (RR)= 0.82, 95% confidence interval (CI) 0.37–1.79], lower NPC-specific mortality was noticed among participants from the screening group versus the control group (RR = 0.22, 95% CI 0.09–0.49).ConclusionIgA antibodies against EBV can identify high-risk population and was effective in screening for early asymptomatic NPC. Although the mortality reduction was not significant in the primary end point, we noted encouraging evidence of a mortality reduction in screening participants in this interim analysis.Clinical trial numberNCT00941538.
Identification of a PTPN22 Missense Variant As a General Genetic Risk Factor for Drug-Induced Liver Injury
Authors: Paul B. Watkins, Paola Nicoletti, Elizabeth Cirulli, Karen Abramson, Raul J. Andrade, Einar Bjornsson, Naga P. Chalasani, Robert J. Fontana, Pär Hallberg, Yi-Ju Li, Maribel Lucena, Nanye Long, Miriam Molokhia, Mathew Nelson, Joseph Odin, Munir Pirmohamed, Thorunn Rafnar, Jose Serrano, Karen Stefansson, Andrew Stolz, Ann Daly, Guruprasad P. Aithal
Journal: Hepatology (2018)

Identification of a PTPN22 Missense Variant As a General Genetic Risk Factor for Drug-Induced Liver Injury